Merck KGaA readies new round of acquisitions and partnerships
Merck KGaA says it will take some of the billions it made off the sale of its generic business and go after new acquisitions. Executive Director Stefan Oschmann says that one area that the company plans to grow is in vaccines, though he isn't looking for any mega-mergers. He's also interested in biotech companies with late-stage development projects or promising research platforms. The company has a big appetite for deal-making. Merck inked 35 acquisitions and partnerships last year.
- here's the report on Merck from Javno
Be the first to comment
Comments
By Anonymous | Posted 4:49pm | May 15, 2007
Merck KGaA? Oschmann was an executive for the American Merck & Co. (two different companies!) last time I talked to him... Did I not get something, or did someone throw together two pieces of news that were completely unrelated???
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
